• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CNS Response Retains McCloud Communications to Execute a Strategic Investor Relations Program

Posted on: Monday, 25 August 2008, 12:01 CDT

CNS Response, Inc. (OTCBB: CNSO), a life sciences data company, announced today that it has retained McCloud Communications, LLC to develop and execute a comprehensive investor awareness program focused on enhancing shareholder value and visibility within the financial community. The program will include financial communications, investor conferences, institutional targeting and the initiation of equity research.

"CNS Response is the only company providing physicians with a patented technology that can significantly reduce the trial and error associated with treating behavioral and addictive illnesses," commented McCloud Managing Member Marty Tullio. "Given the growth potential of CNS Response through current corporate initiatives, now is the time to communicate their story and achievements to the financial community. We are pleased to be a part of the CNS Response team."

"We have made significant progress over the past nine months on a number of fronts, including clinical studies, physician convenience and strategic corporate relationships," said CNS Response CEO Leonard Brandt. "We expect a series of key results to be announced over the next six months, and it has become a corporate priority to share these successes with our shareholders, members of the financial community, as well as doctors, payers, patients and their families. To make sure we have a proactive shareholder and financial communications program in place, we interviewed a number of firms and selected McCloud Communications. With McCloud we found an understanding and appreciation of our strategic business goals, along with the energy and commitment to assist the CNS team in delivering our story to our targeted audiences."

About CNS Response, Inc.

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

 Investor and Media Contacts: Marty Tullio Managing Member McCloud Communications, LLC 949.553.9748 Email Contact

SOURCE: CNS Response, Inc.

Source: MARKET WIRE

More News in this Category